GAS2L3

Summary

GAS2L3 (growth arrest specific 2 like 3, HGNC:27475) is a protein-coding gene on chromosome 12q23.1, encoding GAS2-like protein 3 (Q86XJ1). Cytoskeletal linker protein.

Enables actin binding activity and microtubule binding activity. Involved in actin cytoskeleton organization and microtubule cytoskeleton organization. Located in actin cytoskeleton and microtubule cytoskeleton.

Source: NCBI Gene 283431 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 104 total
• MANE Select transcript: NM_174942

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:27475
Approved symbol	GAS2L3
Name	growth arrest specific 2 like 3
Location	12q23.1
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000139354
Ensembl biotype	protein_coding
OMIM	617224
Entrez	283431

Gene structure

Transcript identifiers

Ensembl transcripts: 20 — 16 protein_coding, 2 retained_intron, 1 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000266754, ENST00000537247, ENST00000539410, ENST00000547739, ENST00000547754, ENST00000548067, ENST00000548113, ENST00000550295, ENST00000552854, ENST00000851885, ENST00000851886, ENST00000851887, ENST00000851888, ENST00000851889, ENST00000851890, ENST00000851891, ENST00000851892, ENST00000851893, ENST00000851894, ENST00000851895

RefSeq mRNA: 4 — MANE Select: NM_174942 NM_001303130, NM_001303131, NM_001363672, NM_174942

CCDS: CCDS76590, CCDS9079

Canonical transcript exons

ENST00000547754 — 10 exons

Exon	Start	End
ENSE00000937761	100618449	100618587
ENSE00000937762	100622275	100622382
ENSE00002350286	100623562	100628288
ENSE00002370999	100591736	100591856
ENSE00002401819	100573684	100573785
ENSE00003467750	100617744	100617807
ENSE00003491585	100594875	100594922
ENSE00003555091	100601638	100601753
ENSE00003569688	100600382	100600550
ENSE00003694255	100612000	100612141

Expression profiles

Bgee: expression breadth ubiquitous, 204 present calls, max score 98.57.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 7.7525 / max 218.5841, expressed in 1473 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
127579	6.1696	1420
127580	0.8691	509
127581	0.5046	217
127584	0.2092	90

Top tissues by expression

240 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
trigeminal ganglion	UBERON:0001675	98.57	gold quality
dorsal root ganglion	UBERON:0000044	97.51	gold quality
sural nerve	UBERON:0015488	95.78	gold quality
tibial nerve	UBERON:0001323	95.22	gold quality
epithelial cell of pancreas	CL:0000083	93.29	silver quality
ventricular zone	UBERON:0003053	93.10	gold quality
mucosa of sigmoid colon	UBERON:0004993	89.25	gold quality
pancreatic ductal cell	CL:0002079	88.98	gold quality
buccal mucosa cell	CL:0002336	88.58	gold quality
adrenal tissue	UBERON:0018303	87.54	gold quality
colonic mucosa	UBERON:0000317	87.20	gold quality
secondary oocyte	CL:0000655	86.03	gold quality
ganglionic eminence	UBERON:0004023	86.03	gold quality
visceral pleura	UBERON:0002401	84.56	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	82.56	gold quality
kidney epithelium	UBERON:0004819	81.82	gold quality
skin of hip	UBERON:0001554	81.58	gold quality
ileal mucosa	UBERON:0000331	80.85	gold quality
gall bladder	UBERON:0002110	80.32	gold quality
trabecular bone tissue	UBERON:0002483	80.24	gold quality
rectum	UBERON:0001052	80.23	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	79.99	gold quality
placenta	UBERON:0001987	79.37	gold quality
parietal pleura	UBERON:0002400	79.09	silver quality
jejunal mucosa	UBERON:0000399	78.30	gold quality
stromal cell of endometrium	CL:0002255	78.27	gold quality
calcaneal tendon	UBERON:0003701	77.25	gold quality
oocyte	CL:0000023	77.22	gold quality
amniotic fluid	UBERON:0000173	76.42	gold quality
cartilage tissue	UBERON:0002418	76.26	silver quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	8.14

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

148 targeting GAS2L3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-433-3P	99.98	69.37	1203
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-493-5P	99.96	72.47	2382
HSA-MIR-548AT-5P	99.96	70.83	2666

Literature-anchored findings (GeneRIF, showing 4)

• tubulin acetylation drives GAS2-like 3 localization to MTs and may provide functional insights into the role of GAS2-like 3. (PMID:21561867)
• GAS2L3, a target gene of the DREAM complex, is required for cytokinesis and genomic stability. (PMID:22344256)
• show that the Gas2l3 protein is targeted for ubiquitin-mediated proteolysis by the APC/C(Cdh1) complex, but not by the APC/C(Cdc20) complex, and is phosphorylated by Cdk1 in mitosis (PMID:23469016)
• show that the GAR domain of GAS2L3 is required for localization of GAS2L3 to the constriction zone (PMID:24571573)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	gas2l3	ENSDARG00000045880
mus_musculus	Gas2l3	ENSMUSG00000074802
rattus_norvegicus	Gas2l3	ENSRNOG00000063755

Paralogs (36): SYNE2 (ENSG00000054654), SPTB (ENSG00000070182), ACTN1 (ENSG00000072110), ACTN2 (ENSG00000077522), DSP (ENSG00000096696), DRP2 (ENSG00000102385), SPTBN1 (ENSG00000115306), MACF1 (ENSG00000127603), FLNC (ENSG00000128591), ACTN4 (ENSG00000130402), SYNE1 (ENSG00000131018), MICAL2 (ENSG00000133816), DTNA (ENSG00000134769), MICAL1 (ENSG00000135596), FLNB (ENSG00000136068), SPTBN5 (ENSG00000137877), DTNB (ENSG00000138101), DST (ENSG00000151914), UTRN (ENSG00000152818), SPTBN4 (ENSG00000160460), SPTA1 (ENSG00000163554), CLMN (ENSG00000165959), PKHD1 (ENSG00000170927), SPTBN2 (ENSG00000173898), SYNE3 (ENSG00000176438), PLEC (ENSG00000178209), SMTNL2 (ENSG00000188176), FLNA (ENSG00000196924), SPTAN1 (ENSG00000197694), DMD (ENSG00000198947), PKHD1L1 (ENSG00000205038), DYTN (ENSG00000232125), MICAL3 (ENSG00000243156), ACTN3 (ENSG00000248746), EPPK1 (ENSG00000261150), GAS2L2 (ENSG00000270765)

Protein

Protein identifiers

GAS2-like protein 3 — Q86XJ1 (reviewed: Q86XJ1)

Alternative names: Growth arrest-specific protein 2-like 3

All UniProt accessions (4): Q86XJ1, F8VSB7, G3V1N3, H0YIT6

UniProt curated annotations — full annotation on UniProt →

Function. Cytoskeletal linker protein. May promote and stabilize the formation of the actin and microtubule network.

Subunit / interactions. Interacts (via CH domain) with F-actin. Interacts (via C terminus) with microtubules. Interacts with MAPRE1.

Subcellular location. Cytoplasm. Cytoskeleton.

Tissue specificity. Expressed in the pancreas, heart, liver, placenta, brain, skeletal muscle, kidney and lung.

Domain organisation. The GAR domain modulates the binding strength to each cytoskeletal network.

Similarity. Belongs to the GAS2 family.

RefSeq proteins (4): NP_001290059, NP_001290060, NP_001350601, NP_777602* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001715	CH_dom	Domain
IPR003108	GAR_dom	Domain
IPR036534	GAR_dom_sf	Homologous_superfamily
IPR036872	CH_dom_sf	Homologous_superfamily

Pfam: PF00307, PF02187

UniProt features (18 total): compositionally biased region 8, domain 2, modified residue 2, sequence variant 2, mutagenesis site 2, chain 1, region of interest 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q86XJ1-F1	60.52	0.27

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 441, 570

Mutagenesis-validated functional residues (2):

Position	Phenotype
373–374	no effect on microtubule localization and mapre1 binding; when associated with 461-n-n-462.
461–462	no effect on microtubule localization and mapre1 binding; when associated with 373-n-n-374.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 197 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_TUMORAL_MACROPHAGE_UP, RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP, GAUSSMANN_MLL_AF4_FUSION_TARGETS_A_UP, MOLENAAR_TARGETS_OF_CCND1_AND_CDK4_DN, FISCHER_G2_M_CELL_CYCLE, GOBP_ACTIN_FILAMENT_ORGANIZATION, SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_DN, BOYLAN_MULTIPLE_MYELOMA_C_CLUSTER_UP, PYEON_CANCER_HEAD_AND_NECK_VS_CERVICAL_UP, LIAO_METASTASIS, DODD_NASOPHARYNGEAL_CARCINOMA_UP, GOMF_ACTIN_BINDING, BASAKI_YBX1_TARGETS_DN, FISCHER_DREAM_TARGETS

GO Biological Process (3): microtubule cytoskeleton organization (GO:0000226), actin cytoskeleton organization (GO:0030036), actin crosslink formation (GO:0051764)

GO Molecular Function (4): actin binding (GO:0003779), microtubule binding (GO:0008017), actin filament binding (GO:0051015), protein binding (GO:0005515)

GO Cellular Component (5): cytoplasm (GO:0005737), microtubule (GO:0005874), actin cytoskeleton (GO:0015629), microtubule cytoskeleton (GO:0015630), cytoskeleton (GO:0005856)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cytoskeleton organization	2
cytoskeleton	2
microtubule-based process	1
actin filament-based process	1
actin filament organization	1
cytoskeletal protein binding	1
tubulin binding	1
actin binding	1
protein-containing complex binding	1
binding	1
intracellular anatomical structure	1
cellular anatomical structure	1
microtubule cytoskeleton	1
polymeric cytoskeletal fiber	1
intracellular membraneless organelle	1

Protein interactions and networks

STRING

900 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
GAS2L3	G2E3	Q7L622	611
GAS2L3	WDR76	Q9H967	574
GAS2L3	NCAPD2	Q15021	572
GAS2L3	NUF2	Q9BZD4	559
GAS2L3	CKAP2	Q8WWK9	552
GAS2L3	DLGAP5	Q15398	549
GAS2L3	PIMREG	Q9BSJ6	545
GAS2L3	CKAP5	Q14008	524
GAS2L3	PSRC1	Q6PGN9	523
GAS2L3	DSCC1	Q9BVC3	522
GAS2L3	GINS2	Q9Y248	516
GAS2L3	KIF23	Q02241	506
GAS2L3	CHAF1B	Q13112	488
GAS2L3	CASP8AP2	Q9UKL3	479
GAS2L3	CDCA2	Q69YH5	472

IntAct

27 interactions, top by confidence:

A	B	Type	Score
AURKB	GAS2L3	psi-mi:“MI:0915”(physical association)	0.580
AURKB	GAS2L3	psi-mi:“MI:0403”(colocalization)	0.580
MYL6	GAS2L3	psi-mi:“MI:0915”(physical association)	0.560
ZIC1	GAS2L3	psi-mi:“MI:0915”(physical association)	0.560
GAS2L3	MYL6	psi-mi:“MI:0915”(physical association)	0.560
GAS2L3	TSR2	psi-mi:“MI:0915”(physical association)	0.560
FNDC3B	GAS2L3	psi-mi:“MI:0915”(physical association)	0.560
GAS2L3	BIRC5	psi-mi:“MI:0914”(association)	0.560
BIRC5	GAS2L3	psi-mi:“MI:0914”(association)	0.560
BIRC5	GAS2L3	psi-mi:“MI:0915”(physical association)	0.560
CDCA8	GAS2L3	psi-mi:“MI:0915”(physical association)	0.500
GAS2L3	MFHAS1	psi-mi:“MI:0407”(direct interaction)	0.440
GAS2L3	H1-1	psi-mi:“MI:0915”(physical association)	0.400
DND1	RPSA2	psi-mi:“MI:0914”(association)	0.350
SLC4A1	UPK3BL1	psi-mi:“MI:0914”(association)	0.350
DCTN1	NACA	psi-mi:“MI:2364”(proximity)	0.270
GAS2L3	KIF20A	psi-mi:“MI:0403”(colocalization)	0.270
GAS2L3	SPAST	psi-mi:“MI:0403”(colocalization)	0.270
TSR2	GAS2L3	psi-mi:“MI:0915”(physical association)	0.000
FNDC3B	GAS2L3	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (52): GAS2L3 (Affinity Capture-MS), GAS2L3 (Affinity Capture-MS), GAS2L3 (Proximity Label-MS), GAS2L3 (Affinity Capture-MS), GAS2L3 (Affinity Capture-MS), GAS2L3 (Affinity Capture-MS), GAS2L3 (Affinity Capture-MS), GAS2L3 (Affinity Capture-MS), GAS2L3 (Affinity Capture-MS), GAS2L3 (Affinity Capture-MS), GAS2L3 (Affinity Capture-MS), GAS2L3 (Affinity Capture-MS), GAS2L3 (Affinity Capture-MS), GAS2L3 (Affinity Capture-RNA), GAS2L3 (Reconstituted Complex)

ESM2 similar proteins: A0JMZ4, D3YUB6, D4A0X3, E9Q555, F1MJR8, F1QB81, P0C2N5, P51957, P56715, Q0VF22, Q14699, Q1X8D7, Q29RJ0, Q2PFD7, Q2T9I9, Q3U8K7, Q3ULZ2, Q3UPF5, Q3UWW6, Q5DW34, Q5EXX3, Q5REF4, Q5SSZ5, Q5SW75, Q5T7B8, Q5XKL5, Q5ZLE9, Q60DG4, Q65Z40, Q6DFV3, Q6KAQ7, Q6NRK3, Q6NWW5, Q6PI47, Q76I76, Q76I79, Q7TSH4, Q7Z5K2, Q811D2, Q86XJ1

Diamond homologs: A0A1L8H8C0, A0A1L8HFX9, D3ZHV2, D3ZUE1, O43903, O94854, P11862, Q03001, Q3UWW6, Q5SSG4, Q69ZZ9, Q86XJ1, Q8JZP9, Q8NHY3, Q91ZU6, Q99501, Q9QXZ0, Q9UPN3, Q9W3Y4

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
GAS2L3	up-regulates	F-actin_assembly

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 17 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
M Phase	5	30.0×	3e-05
Cell Cycle, Mitotic	5	21.9×	7e-05
Cell Cycle	5	16.4×	1e-04

GO biological processes:

GO term	Partners	Fold	FDR
mitotic cytokinesis	5	86.4×	2e-07

Disease & clinical

Clinical variants and AI predictions

ClinVar

104 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	86
Likely benign	9
Benign	5

Top pathogenic / likely-pathogenic (0)

SpliceAI

1747 predictions. Top by Δscore:

Variant	Effect	Δscore
12:100573781:GCCTG:G	donor_gain	1.0000
12:100573783:CTGGT:C	donor_loss	1.0000
12:100573784:TG:T	donor_gain	1.0000
12:100573784:TGG:T	donor_loss	1.0000
12:100573785:GG:G	donor_gain	1.0000
12:100573786:G:GG	donor_gain	1.0000
12:100573786:GTG:G	donor_loss	1.0000
12:100573787:T:G	donor_loss	1.0000
12:100594874:GAAAA:G	acceptor_gain	1.0000
12:100594923:G:GG	donor_gain	1.0000
12:100600379:TAGGT:T	acceptor_loss	1.0000
12:100600380:A:AG	acceptor_gain	1.0000
12:100600380:A:T	acceptor_loss	1.0000
12:100600381:G:GA	acceptor_loss	1.0000
12:100600381:G:GG	acceptor_gain	1.0000
12:100600381:GGT:G	acceptor_gain	1.0000
12:100600381:GGTA:G	acceptor_gain	1.0000
12:100600381:GGTAT:G	acceptor_gain	1.0000
12:100600546:ATTAG:A	donor_loss	1.0000
12:100600547:TTAG:T	donor_loss	1.0000
12:100600549:AGGT:A	donor_loss	1.0000
12:100600550:GGTGA:G	donor_loss	1.0000
12:100600552:T:G	donor_loss	1.0000
12:100601634:TTAG:T	acceptor_loss	1.0000
12:100601636:A:AG	acceptor_gain	1.0000
12:100601637:G:GG	acceptor_gain	1.0000
12:100601749:CAGGG:C	donor_gain	1.0000
12:100601750:AGGG:A	donor_gain	1.0000
12:100601751:GGG:G	donor_gain	1.0000
12:100601751:GGGG:G	donor_gain	1.0000

AlphaMissense

4459 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:100612051:T:C	F119L	1.000
12:100612053:C:A	F119L	1.000
12:100612053:C:G	F119L	1.000
12:100623604:T:A	W267R	1.000
12:100623604:T:C	W267R	1.000
12:100623606:G:C	W267C	1.000
12:100623606:G:T	W267C	1.000
12:100600524:T:C	L54P	0.999
12:100600532:T:A	W57R	0.999
12:100600532:T:C	W57R	0.999
12:100612058:C:A	A121D	0.999
12:100612061:G:C	R122P	0.999
12:100612072:G:C	A126P	0.999
12:100612079:T:C	F128S	0.999
12:100617780:T:C	L161P	0.999
12:100617795:G:C	R166P	0.999
12:100622344:G:A	G240R	0.999
12:100622344:G:C	G240R	0.999
12:100622348:G:C	R241P	0.999
12:100622350:T:C	Y242H	0.999
12:100622350:T:G	Y242D	0.999
12:100622351:A:C	Y242S	0.999
12:100622354:G:C	R243P	0.999
12:100622374:T:C	F250L	0.999
12:100622376:T:A	F250L	0.999
12:100622376:T:G	F250L	0.999
12:100622381:G:T	R252I	0.999
12:100623581:T:A	V259D	0.999
12:100623584:T:C	M260T	0.999
12:100623584:T:G	M260R	0.999

dbSNP variants (sampled 300 via entrez): RS1000024468 (12:100610771 CA>C,CAA), RS1000075347 (12:100621928 T>A,C), RS1000278444 (12:100589365 C>G), RS1000307210 (12:100573425 C>T), RS1000426562 (12:100622242 C>A,T), RS1000491900 (12:100596085 C>G,T), RS1000545936 (12:100603608 C>A,T), RS1000606224 (12:100603227 C>T), RS1000670293 (12:100615480 T>C), RS1000675736 (12:100615136 G>A), RS1000731666 (12:100622858 AGAATCAGTAT>A), RS1000740625 (12:100601434 C>G,T), RS1000912642 (12:100571842 T>C,G), RS1000915226 (12:100616685 G>A), RS1001102642 (12:100610111 A>G)

Disease associations

OMIM: gene MIM:617224 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST001827_1	Squamous cell carcinoma	1.000000e-10

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

44 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	decreases expression, decreases methylation	3
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	3
Acetaminophen	increases expression, affects expression	2
Cadmium	decreases expression, increases abundance	2
Estradiol	decreases expression, increases expression, affects cotreatment	2
Cyclosporine	decreases expression	2
Cadmium Chloride	decreases expression, increases abundance	2
aristolochic acid I	decreases expression	1
GSK-J4	increases expression	1
FR900359	decreases phosphorylation	1
propionaldehyde	decreases expression	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	affects cotreatment, increases expression	1
perfluoro-n-nonanoic acid	decreases expression	1
2-palmitoylglycerol	increases expression	1
abrine	increases expression	1
jinfukang	affects cotreatment, decreases expression	1
incobotulinumtoxinA	decreases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Dasatinib	decreases expression	1
Resveratrol	affects cotreatment, increases expression	1
Temozolomide	increases expression	1
Sunitinib	decreases expression	1
Air Pollutants	decreases expression, increases abundance	1
Azathioprine	decreases expression	1
Benzene	increases expression	1
Calcitriol	decreases expression, affects cotreatment	1
Cisplatin	affects cotreatment, decreases expression	1
Coumestrol	affects cotreatment, increases expression	1
Doxorubicin	decreases expression	1
Formaldehyde	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.